-
EP3018145
European procedure
Extract from the Register of European Patents
EP About this file: EP3018145
| EP3018145 - MEANS AND METHODS FOR TREATING DLBCL [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 02.03.2018 Database last updated on 03.09.2024 | |
| Former | Grant of patent is intended Status updated on 10.10.2017 | ||
| Former | Request for examination was made Status updated on 20.09.2017 | ||
| Former | Grant of patent is intended Status updated on 08.05.2017 | ||
| Former | Request for examination was made Status updated on 11.11.2016 | Most recent event Tooltip | 13.12.2019 | Opposition procedure terminated - date of legal effect published | published on 15.01.2020 [2020/03] | Applicant(s) | For all designated states Amgen Research (Munich) GmbH Staffelseestrasse 2 81477 München / DE | [2016/19] | Inventor(s) | 01 /
ZUGMAIER, Gerhard c/o Amgen Research (Munich) GmbH Staffelseestrasse 2 81477 München / DE | 02 /
NAGORSEN, Dirk c/o Amgen Research (Munich) GmbH Staffelseestrasse 2 81477 München / DE | 03 /
SCHEELE, Juergen c/o Amgen Research (Munich) GmbH Staffelseestrasse 2 81477 München / DE | [2016/19] | Representative(s) | Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE | [N/P] |
| Former [2018/14] | Schiweck, Weinzierl & Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE | ||
| Former [2016/19] | Schiweck, Weinzierl & Koch European Patent Attorneys Landsberger Straße 98 80339 München / DE | Application number, filing date | 15195076.3 | 27.10.2011 | [2016/19] | Priority number, date | US20100407107P | 27.10.2010 Original published format: US 407107 P | [2016/19] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3018145 | Date: | 11.05.2016 | Language: | EN | [2016/19] | Type: | B1 Patent specification | No.: | EP3018145 | Date: | 04.04.2018 | Language: | EN | [2018/14] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 17.03.2016 | Classification | IPC: | C07K16/28, C07K16/46, A61K39/395, A61P35/00 | [2016/19] | CPC: |
C07K16/2809 (EP,EA,IL,US);
A61K39/395 (KR);
C07K16/2803 (EP,EA,IL,US);
A61K39/39558 (EP,EA,IL,US);
A61P35/00 (EP);
A61P43/00 (EP);
C07K16/28 (KR);
C07K16/46 (KR);
A61K2039/505 (EP,EA,IL,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/50] |
| Former [2016/19] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Extension states | BA | 07.11.2016 | ME | 07.11.2016 | Title | German: | MITTEL UND VERFAHREN ZUR BEHANDLUNG VON DLBCL | [2016/19] | English: | MEANS AND METHODS FOR TREATING DLBCL | [2016/19] | French: | MOYENS ET MÉTHODES DE TRAITEMENT DU LYMPHOME B DIFFUS À GRANDES CELLULES | [2016/19] | Examination procedure | 18.11.2015 | Date on which the examining division has become responsible | 07.11.2016 | Amendment by applicant (claims and/or description) | 07.11.2016 | Examination requested [2016/50] | 09.05.2017 | Communication of intention to grant the patent | 14.09.2017 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 11.10.2017 | Communication of intention to grant the patent | 06.02.2018 | Receipt of the translation of the claim(s) | 20.02.2018 | Fee for grant paid | 20.02.2018 | Fee for publishing/printing paid | Parent application(s) Tooltip | EP11787633.4 / EP2632954 | Divisional application(s) | EP18164175.4 / EP3412687 | EP20162873.2 Application refused : 20.08.2020 | Opposition(s) | Opponent(s) | 01
21.12.2018
08.08.2019
WITHDRAWN Affimed GmbH Technologie Park Im Neuenheimer Feld 582 69120 Heidelberg / DE Opponent's representative Schmitz, Georg Huber & Schüssler Patentanwälte Truderinger Strasse 246 81825 München / DE | [2019/38] |
| Former [2019/06] | |||
| Opponent(s) | 01
21.12.2018
WITHDRAWN Affimed GmbH Technologie Park Im Neuenheimer Feld 582 69120 Heidelberg / DE Opponent's representative Schmitz, Georg Huber & Schüssler Patentanwälte Truderinger Strasse 246 81825 München / DE | 18.01.2019 | Invitation to proprietor to file observations on the notice of opposition | 28.05.2019 | Reply of patent proprietor to notice(s) of opposition | 28.08.2019 | Despatch of communication that the opposition procedure will be closed | 07.09.2019 | Legal effect of closure of opposition procedure [2020/03] | Fees paid | Renewal fee | 18.11.2015 | Renewal fee patent year 03 | 18.11.2015 | Renewal fee patent year 04 | 18.11.2015 | Renewal fee patent year 05 | 11.10.2016 | Renewal fee patent year 06 | 11.10.2017 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO2007068354 (MICROMET AG [DE], et al) [I] 1-15 * page 16, paragraph 2 * * claims 1-21 *; | [XPI]WO2011051307 (MICROMET AG [DE], et al) [XP] 1,3,5-14 * page 15, line 25 - line 29 * * claims 2,8-31,36,37,42-44 * [I] 2,4; | [I] - WILSON WYNDHAM H ET AL, "Novel disease targets and management approaches for diffuse large B-cell lymphoma", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, (20100801), vol. 51, no. supplement 1, doi:10.3109/10428194.2010.500045, ISSN 1042-8194, pages 1 - 10, XP008135253 [I] 1-15 * abstract * * page 1, column l, paragraph 1 - page 2, column l, paragraph 2 * * page 7, column l, paragraph 2 * * page 8, column r, paragraph l * * table II * DOI: http://dx.doi.org/10.3109/10428194.2010.500045 | [I] - SOPHIE DUPIRE ET AL, "Targeted treatment and new agents in diffuse large B cell lymphoma", INTERNATIONAL JOURNAL OF HEMATOLOGY, (20100701), vol. 92, no. 1, doi:10.1007/s12185-010-0609-6, ISSN 0925-5710, pages 12 - 24, XP055023306 [I] 1-15 * abstract * * page 12, column l, paragraph l - column r, paragraph 2 * * page 21, column l, paragraph 2 * * table 1 * DOI: http://dx.doi.org/10.1007/s12185-010-0609-6 | [I] - QUINTÁS-CARDAMA ALFONSO ET AL, "Investigational immunotherapeutics for B-cell malignancies.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 10 FEB 2010 LNKD- PUBMED:20048186, (20100210), vol. 28, no. 5, ISSN 1527-7755, pages 884 - 892, XP009157966 [I] 1-15 * page 884, column l, paragraph 1 - column r, paragraph 2 * * page 888, column l, paragraph l * * page 889, column l, paragraph 2 - column r, paragraph 1 * DOI: http://dx.doi.org/10.1200/JCO.2009.22.8254 | [I] - BARGOU RALF ET AL, "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, (20080815), vol. 321, no. 5891, doi:10.1126/SCIENCE.1158545, ISSN 0036-8075, pages 974 - 977, XP002615656 [I] 1-15 * the whole document * DOI: http://dx.doi.org/10.1126/SCIENCE.1158545 | [A] - NG ET AL, "Diffuse Large B-Cell Lymphoma", SEMINARS IN RADIATION ONCOLOGY, SAUNDERS, PHILADELPHIA, PA, US, (20070623), vol. 17, no. 3, doi:10.1016/J.SEMRADONC.2007.02.002, ISSN 1053-4296, pages 169 - 175, XP022128313 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.semradonc.2007.02.002 | by applicant | WO9954440 | EP0623679 | WO2004106381 | WO2005052004 | WO2007068354 | WO2008119565 | - ARMITAGE, BLOOD, (2007), vol. 110, no. 1, pages 29 - 36 | - MOLNAR; LAPIN; GOOTHUIS, NEUROONCOL., (1995), vol. 25, no. 1, pages 19 - 28 | - ALIZADEH ET AL., NATURE, (2000), vol. 403, pages 503 - 511 | - SHIPP ET AL., NAT MED, (2002), vol. 8, pages 68 - 74 | - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, pages 443 - 453 | - SMITH; WATERMAN, ADV. APPL. MATH, (1981), vol. 2, pages 482 - 489 | - CRICK, J MOL BIOL, vol. 19, (1966), pages 548 - 55, URL: http://en.wikipedia.org/wiki/Wobb!e__Hypothesis | - CHESON ET AL., J. CLIN. ONCOL., (2007), vol. 25, no. 5, pages 579 - 586 | - BAEK ET AL., METHODS ENZYMOL., (2003), vol. 362, pages 240 - 9 | - NIGAVEKAR ET AL., PHARM RES., (2004), vol. 21, no. 3, pages 476 - 83 | - BERGE, S. M. ET AL., J. PHARM. SCI., (1977), vol. 66, pages 1 - 19 | - ARTHRITIS RHEUM., (200602), vol. 54, no. 2, pages 613 - 20 | - DUBOIS, ARCH INT MED, (1916), vol. 17, pages 863 - 871 | - HAYCOCK, THE JOURNAL OF PEDIATRICS, (1978), vol. 93, no. 1, pages 62 - 66 | - GEHAN, CANCER CHEMOTHER REP, (1970), vol. 54, pages 225 - 35 | Opposition | WO2007068354 | US2008138336 | US2009285808 | - BARGOU R et al., "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody", Science, (20080815), vol. 321, no. 5891, pages 974 - 977, XP002615656 DOI: http://dx.doi.org/10.1126/SCIENCE.1158545 | - RALF BARGOU et al., "Supporting Online Material for '' Tumor Regression by Very Low Doses of a T Cell -Engaging Antibody", Science, vol. 321, (20080815), page 974, URL: www.sciencemae.ore/cgi/content/full/321/5891/974/DCl, XP055500980 DOI: http://dx.doi.org/10.1126/science.1158545 | - MATTHIAS KLINGER, "Wirkmechanismus des bispezifischen anti- CD 19 x ant- CD 3 BiTE- Antikörpers MT 103 in Patienten mit rezidivem indolenten B-Zell-Non-Hodgkin- Lymphom", Doctoral Thesis University of Tübingen, (20090926), URL: https://publikationen.uni-tuebingen.de/xmlui/bitstream/handle/10900/43908/pdf/Dissertation_Matthias_Klinger.pdf?sequence=1, XP055541894 | - COIFFIER et al., "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study", Blood, (19980000), vol. 92, no. 6, pages 1927 - 1932, XP055541896 |